Loading…
Loading…
AVCRF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AVCRF and 80,000+ other tickers.
See exactly how AVCRF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AVCRF and 80,000+ other tickers.
Avricore Health Inc. is a Canadian company specializing in health data and immediate diagnostic technologies. Its core offering is HealthTab, a proprietary platform providing precise, lab-quality point-of-care testing specifically designed for pharmacy environments. The company boasts significant strategic alliances, notably with Shoppers Drug Marts and Abbott. Founded in 1996, the Vancouver, Canada-based enterprise previously operated as Vanc Pharmaceuticals Inc. before officially adopting the name Avricore Health Inc. in October 2018.
VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement with Abbott, a global healthcare company, to supply and distribute Abbott's point-of-care testing products through the HealthTab™ platform in the UK.
VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces that, further to its news release dated May 20, 2026, the Company has closed its non-brokered private placement for gross proceeds of $1,254,000 by issuing 25,080,000 Units at $0.05 per Unit on June 16, 2026.
VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) announces a non-brokered private placement of up to 25,000,000 units ("Units") at a price of $0.05 per unit for gross proceeds of $1,250,000. (the "Private Placement"). The proceeds will be used to expand the Company's HealthTab™ network and for general working capital purposes.
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) announces HealthTab™ has now screened more than 3,500 patients in community pharmacies across North East and North Central London. During an initial one-month pilot of HbA1c testing for diabetes screening, the Company completed 2,295 HbA1c tests across 57 locations, achieving a monthly per-location average 10 times higher than previously achieved in Canada.
VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) today announced the planned expansion of its HealthTab™ platform across North East London (NEL), with deployment to an additional 70 community pharmacy sites, building on the success of its NHS-linked cardiovascular programmes delivered in collaboration with Barts Health NHS Trust.